Tarlatamab |
Katalog-Nr.GC72408 |
Tarlatamab (AMG-757) ist ein bispezifischer T-Zell-Engager (BiTE)-Antikörper, der auf Delta-like Ligand 3 (DLL3) abzielt.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2307488-83-9
Sample solution is provided at 25 µL, 10mM.
Tarlatamab (AMG-757; 0-10 nM; 48 hours) has potent, specific cytotoxic activity against DLL3-expressing SCLC cell lines in vitro[1].
Tarlatamab (0-10 nM; 4-72 h) increased granzyme B levels and cytotoxicity over time, with maximal signal observed at 48 hours. Markers of T-cell activation or inflammation, CD69, CD71, PD-1, and PD-L1 (37-39) were upregulated[1].
Tarlatamab (AMG-757; 3 mg/kg; IP; once weekly for 3 weeks) drives tumor regression in mouse models of SCLC[1].
Tarlatamab (IP; 12 μg/kg; single dose) has a mean half-life of 234 hours (9.8 days), a mean clearance of 0.487 mL/hour/kg and a steady-state volume of distribution of 146 mL/kg in nonhuman primates (NHPs)[1].
References:
[1]. Michael J Giffin, et al. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. Clin Cancer Res. 2021 Mar 1;27(5):1526-1537.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *